Automated insulin delivery systems

Insulet to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 22, 2022
Mobile, Wireless, Technology, Medical Devices, Medical Supplies, Diabetes, Other Technology, Health Technology, Biotechnology, General Health, Health, Insulin pump, Eastern Time Zone, Automated insulin delivery systems, Conference, Corporation, Diabetes, POD, Medical device

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at two upcoming investor conferences:

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at two upcoming investor conferences:
    The Nasdaq 47th Investor Conference in London on Tuesday, December 6, 2022 at 6:30 a.m. (Eastern Time)
    The J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Tuesday, January 10, 2023 at 1:30 p.m. (Eastern Time).
  • Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
  • Omnipod is a registered trademark of Insulet Corporation.

Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 Controller

Retrieved on: 
Monday, November 14, 2022
Other Health, Men, Consumer Electronics, Consumer, Medical Devices, Technology, Other Consumer, Women, Seniors, Other Technology, Health, Diabetes, FDA, Insulin pump, Android, USB, Automated insulin delivery systems, Customer service, Corporation, DASH, Security (finance), Injury, Risk, Annual report, Diabetes, Controller, POD, Knowledge, Medical device, Online shopping

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable.
  • This does not impact the Omnipod 5 Pod, the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, or compatible Android smartphone devices that have the Omnipod 5 App installed.
  • The excess heat may cause minor burns if those areas of the Controller are touched or could lead to fire.
  • Omnipod, Omnipod DASH and Omnipod 5 are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

Retrieved on: 
Thursday, November 10, 2022
GLOBE, PAH, Inhalable insulin, T1D, Health, Poster, Adult, Hypertensive emergency, NTM, U.S. Securities and Exchange Commission, AID, Impact, PPGE, TI, Meal, Diabetes, ABC, Risk, Hypoglycemia, Insulin, Glucose, Inhalation, Professional corporation, Annual report, Doctor of Pharmacy, RAA, Freedom, Degenerative disease, MannKind Corporation, Engineering, Patient, Automated insulin delivery systems, Blood glucose monitoring, CEO, Security (finance), Form 8-K, Medical Affairs Bureau, Medical device, Pharmaceutical industry, Safety, Facebook

No severe hypoglycemia was observed in the TI groups using the higher dose conversion method described below.

Key Points: 
  • No severe hypoglycemia was observed in the TI groups using the higher dose conversion method described below.
  • MannKind remains committed to improving options for mealtime control for patients living with diabetes.
  • MannKind also sponsored Poster# DESB2134D Simulating the Impact of Diabetes Therapy Engagement on Outcomes which will be presented by Lane Desborough, CEO of Nudge BG.
  • AFREZZA, TECHNOSPHERE and MANNKIND are registered trademarks of MannKind Corporation.

Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Retrieved on: 
Friday, November 4, 2022
Software, Biotechnology, Pharmaceutical, Health, FDA, Diabetes, Medical Devices, Technology, Company, PDM, Risk, Corporation, Automated insulin delivery systems, PDMS, Death, FDA, DASH, Knowledge, Compliance, Customer service, Annual report, U.S. Securities and Exchange Commission, Injury, NASDAQ, POD, Diabetes, Insulin pump, Security (finance), Software, Medical device

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH Personal Diabetes Managers (PDMs) distributed globally.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH Personal Diabetes Managers (PDMs) distributed globally.
  • As previously communicated to Omnipod DASH users, Insulet has identified an update to the Omnipod DASH PDM that will resolve this issue.
  • The Company expects to begin shipping updated Omnipod DASH PDMs to all current Omnipod DASH customers in the coming months.
  • This Medical Device Correction does not affect Omnipod DASH Pods, the Omnipod Insulin Management System, or the Omnipod 5 Automated Insulin Delivery System.

Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, September 22, 2022
Pharmaceutical, Health, Diabetes, Medical Devices, Consumer Electronics, Health Technology, Technology, Mobile, Wireless, Corporation, Eastern Time Zone, POD, Company, Automated insulin delivery systems, Technology, Investor relations, Insulin pump, Diabetes, NASDAQ, Medical device

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets.
  • In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
  • Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Retrieved on: 
Monday, August 22, 2022
Other Consumer, Manufacturing, Women, Teens, Parenting, Men, Children, Baby, Maternity, Family, Medical Devices, Consumer, Consumer Electronics, Technology, General Health, FDA, Diabetes, Other Manufacturing, Health, Glycated hemoglobin, Technology, POD, Caregiver, Ageing, Bonnie Sherr Klein, Dexcom, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, Time, Doctor of Philosophy, G6, Food, Corporation, AID, Medical director, Insulin, CGM, Company, FDA, T1D, Diabetes, Hypoglycemia, 5, Automated insulin delivery systems, Family, Medical device, FRACP

Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022.

Key Points: 
  • Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022.
  • Omnipod 5 has allowed our family to think less about diabetes, said Kara Hornbuckle, an Omnipod 5 user with two children also using the system.
  • in Diabetes Care 4,Omnipod 5 significantly improved time in range, and reduced HbA1c and time in hypoglycemia (
  • Omnipod, Omnipod 5, and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions.

Insulet to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, August 5, 2022
Technology, Medical Devices, Medical Supplies, Diabetes, Other Technology, Health Technology, Other Health, Biotechnology, General Health, Health, Morgan Stanley, Technology, POD, Corporation, NASDAQ, Diabetes, Canaccord Genuity, Morgan, Insulin pump, Conference, Automated insulin delivery systems, Pharmaceutical industry, Medical device, Eastern Time Zone

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time):

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at four upcoming investor conferences (all Eastern Time):
    The Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 4:30 p.m.
  • The Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 3:30 p.m.
  • Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

Retrieved on: 
Thursday, June 30, 2022
Medical Supplies, Consumer Electronics, Health, Medical Devices, Diabetes, Technology, Pharmaceutical, Investor relations, Corporation, NASDAQ, Company, Insulin pump, Eastern Time Zone, POD, Automated insulin delivery systems, Technology, Diabetes, Medical device

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets.
  • In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
  • Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

JDRF Supports Proposed Senate Legislation Addressing the National Insulin Affordability and Accessibility Crisis

Retrieved on: 
Wednesday, June 22, 2022
People, Industry, T1D, JDRF, Method, Pharmacy, Efficiency, Research, Insulin, Act, Health, Volunteering, Automated insulin delivery systems, Food, Senate, Twitter, Legislation, Multimedia, User, Diabetes, Medical device, Pharmaceutical industry, Facebook, Instagram

NEW YORK, June 22, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds the new proposed legislation announced by U.S.

Key Points: 
  • NEW YORK, June 22, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds the new proposed legislation announced by U.S.
  • Senators Jeanne Shaheen (D-NH)and Susan Collins (R-ME).The legislation, named the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act , was announced during a joint press conference which featured JDRF's Chief Mission Strategy Officer, CynthiaRice.
  • "The INSULIN Act, being proposed today by Senators Shaheen and Collins, is a critical step forward for the diabetes community."
  • For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Retrieved on: 
Friday, June 3, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Corporation, Caregiver, AID, Achievement, Goal, Company, DKA, Doctor of Philosophy, 5, ADA, Ageing, American Diabetes Association, Hypoglycemia, Glycated hemoglobin, Diabetes, Technology, Medical director, NASDAQ, Automated insulin delivery systems, Pharmaceutical industry, Birth control, FRACP

Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years with type 1 diabetes over 12 months of use.

Key Points: 
  • Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years with type 1 diabetes over 12 months of use.
  • Im incredibly proud of this remarkable achievement and know that Omnipod 5 will have a big impact on these families.
  • The pivotal trial participants were invited to continue using the Omnipod 5 System in an ongoing 12+ month extension phase, with 100% electing to participate.
  • Results were analyzed after all participants had completed a total of 12 months of Omnipod 5 use (three months in the pivotal trial and nine months in the extension phase).